Skip to content
worth noting New models

Microsoft Research published the RetroChimera model for predicting molecular retrosynthesis

only one source so far

Microsoft Research published the RetroChimera model in Nature, a combination of the transformer model R-SMILES 2 and the graph network NeuralLoc for predicting molecular retrosynthesis. According to the company, chemists in blind tests prefer its synthesis proposals over older methods. The model is on GitHub under the MIT license and…

The research division Microsoft Research published the RetroChimera model in the journal Nature, a framework for predicting retrosynthesis — a process in which a target molecule is broken down backwards into simpler starting materials so that it can actually be made in a laboratory. The model combines two different approaches: R-SMILES 2, a transformer model that generates molecular precursors directly from data (flexible but prone to hallucinations), and NeuralLoc, a model based on a graph neural network that selects and applies reaction templates trained on data (more accurate but limited to known templates). RetroChimera combines the ranked predictions from both models using a learned voting mechanism that weights their proposals at individual positions in the ranking according to their reliability.

According to Microsoft, chemists with PhDs in blind tests preferred predictions for individual reactions from RetroChimera over predictions from both component models, over older established methods and over recorded reactions from the scientific literature. According to the source, the model performs well on both common and rare reaction types.

RetroChimera is available on GitHub under the MIT license and is also accessible through the Microsoft Foundry service; the company provides instructions for obtaining the trained model (checkpoint) in the repository on GitHub. Microsoft Research states that the aim is to accelerate the cycle of designing, making and testing molecules across fields such as drug development or smart materials design, and, in combination with laboratory automation, it expects progress towards self-improving systems for planning and carrying out synthesis.

What changed

Why it matters

According to the source, planning the synthesis of a new molecule today is largely a manual, time-consuming and costly process that slows the development of both drugs and materials. An automated tool with an open license allows chemists to try designing synthetic routes and potentially incorporate this into their own research without having to build a similar system from scratch, and, according to the company, it may enable them to assess a larger number of more complex candidate molecules.

Release card

RetroChimera

Microsoft Research

Inputs
molecules and chemical reactions (SMILES strings and reaction template graphs)
Licence
MIT
Availability
Code on GitHub under the MIT license and access through the Microsoft Foundry service; instructions for obtaining the trained checkpoint are provided in the repository on GitHub.
According to the sources, it is suitable for
  • Designing retrosynthetic routes for target molecules in drug development
  • Designing synthesis for smart materials
  • Accelerating the cycle of designing, making and testing molecules in combination with laboratory automation

According to Microsoft, chemists with PhDs in blind tests preferred predictions for individual reactions from the RetroChimera model over predictions from its component models R-SMILES 2 and NeuralLoc, over older established methods and over recorded reactions from the scientific literature.

The card summarizes information from the article and any dated corrections, with a link to the original source. It is not our assessment of the model. It does not yet have a dedicated editorial profile. Model selection and other announcements →

Relevant practical impact

What this means

01

For a business

Companies developing drugs or new materials gain an open-source tool that, according to Microsoft Research, makes planning molecular synthesis faster and cheaper — a step in the development cycle that has so far been manual, time-consuming and costly.

Development
What to decide R&D teams in pharmaceutical or materials research can try RetroChimera from the GitHub repository (MIT license) or through the Microsoft Foundry service and compare its synthesis proposals with existing approaches.
More business impacts →
chemie GNN molekulární design RetroChimera retrosyntéza transformer

Check the original

Event sources

only one source so far · 1 publisher, 0 independent. We count feeds from the same owner only once.

1
Microsoft Research Blog research source · first detected Improving synthesis prediction of small molecules at scale with RetroChimera